Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.43 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.37 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997989 | 1.00 | PPARG (0.43) | PPARGGPR132OXER1FPR2ALDH1A1 | |
| SCHEMBL3002175 | 0.89 | PPARG (0.51) | PPARGGPR132OXER1ALDH1A1LTB4R | |
| SCHEMBL3002177 | 0.89 | PPARG (0.51) | PPARGGPR132OXER1ALDH1A1LTB4R | |
| SCHEMBL13839680 | 0.86 | TSHR (0.40) | PPARGOXER1ALDH1A1LTB4RLTB4R2 | |
| SCHEMBL11584492 | 0.86 | TSHR (0.40) | PPARGOXER1ALDH1A1LTB4RLTB4R2 | |
| SCHEMBL11584490 | 0.86 | TSHR (0.40) | PPARGOXER1ALDH1A1LTB4RLTB4R2 | |
| SCHEMBL16675142 | 0.81 | FPR2 (0.53) | PPARGGPR132OXER1FPR2ALDH1A1 | |
| SCHEMBL24235134 | 0.77 | FPR2 (0.56) | PPARGGPR132OXER1FPR2ALDH1A1 | |
| SCHEMBL13569839 | 0.77 | OXER1 (0.54) | OXER1FPR2ALDH1A1LTB4RLTB4R2 | |
| SCHEMBL11587353 | 0.73 | MEN1 (0.53) | PPARGALDH1A1LTB4RLTB4R2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100191019-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-07-29 | — | — | US | disclosed |
| EP-2183622-A1 | LIGHT-SHIELDING FILM | Nippon Shokubai Co., Ltd. (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2178399-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009014264-A1 | LIGHT-SHIELDING FILM | NIPPON SHOKUBAI CO., LTD. (JP) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009009916-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100191019-A1 | Organic Compounds | OR10J3, ALOX5, OR51E2 | PPARG 115/4885GPR132 3709/4885OXER1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.